Patents Examined by Katherine Peebles
  • Patent number: 11406596
    Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 9, 2022
    Assignee: NICOX OPHTHALMICS, INC.
    Inventors: Jean-Michel Bukowski, Akshay Nadkarni, José L. Boyer, Brigitte Duquesroix-Chakroun, Tomas Navratil
  • Patent number: 11395831
    Abstract: Disclosed herein are new compositions comprising (1) an antibacterial component comprising (a) a complex comprising (i) an active pharmaceutical ingredient (API) wherein the active pharmaceutical ingredient is tobramycin, a similar compound, or a derivative of either thereof and (ii) a complexing agent, or (b) a derivative of tobramycin or a similar compound comprising one or more conjugates/derivatizing groups, wherein the complexing agent or conjugate(s) cause a detectable increase in API permeation of corneal cells, retention in corneal cells, or both, as compared to the non-complexed or non-derivatized API, and (2) an effective amount of an anti-inflammatory agent, such as dexamethasone or another dexamethasone compound. This disclosure also describes new methods of using such compositions, producing such compositions, and the like.
    Type: Grant
    Filed: May 22, 2021
    Date of Patent: July 26, 2022
    Assignee: SOMERSET THERAPEUTICS, LLC.
    Inventors: Mandar V Shah, Veerappan Subramanian, Ilango Subramanian, Ojas Prakashbhai Doshi
  • Patent number: 11369579
    Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 28, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11331275
    Abstract: The present invention discloses a bexarotene softgel capsule and a preparation method thereof. The bexarotene softgel capsule including: a softgel capsule shell and contents, in which the contents include bexarotene, low molecular weight polyethylene glycol, high molecular weight polyethylene glycol, and polysorbate. The bexarotene softgel capsule of the formula can avoid a problem of drug degradation caused by high temperature heat release and degassing difficulty in a process of preparing the bexarotene softgel capsule in the prior art while maintaining the drug release characteristics, and the preparation method has a simple production process and can significantly improve a problem of poor dosage uniformity while filling a capsule in the prior art.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: May 17, 2022
    Inventors: Bo Liu, Fuxing Shen, Chao Ding, Xiang Ye
  • Patent number: 11324829
    Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: May 10, 2022
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
  • Patent number: 11304951
    Abstract: The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: April 19, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Srihari Gopal, Raja Venkatasubramanian, Huybrecht T'Jollyn
  • Patent number: 11292640
    Abstract: A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The vial is provided either with a specialised stopper/seal into which a syringe nozzle may be inserted or alternatively a septum seal which may be penetrated by a hypodermic needle. The quantities of gas and liquid and the pressure in the vial are pre-set so that, on connection of a syringe to the vial, a predetermined volume of both gas and liquid is transferred to the syringe, with the intention that the syringe is then used to make a foam by known means. The use of the vial ensures that the ratio of gas to liquid in the foam is standardised, and also provides a convenient way of packaging the gas and liquid and of filling the syringe in a sterile manner.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: April 5, 2022
    Inventors: Anthony David Harman, Jan Willem Marinus Mijers, Nikki Robinson
  • Patent number: 11285093
    Abstract: The present invention relates to the uses of swertiamarin or of a plant extract enriched with swertiamarin, for stimulating the formation or regeneration of the epidermis and/or for stimulating the metabolism of the dermis mainly in the cosmetics field.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: March 29, 2022
    Assignee: International Flavors & Fragrances Inc.
    Inventor: Carine Bezivin
  • Patent number: 11241377
    Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: February 8, 2022
    Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.
    Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
  • Patent number: 11197813
    Abstract: Tattoo removal is disclosed. In an example, a method for removing tattoo ink from skin or resolving a medical condition related to tattoo ink, includes applying a primary solution of beta glucan to a treatment area having tattooed skin. The primary solution stimulates the skin in the treatment area to enhance removal of the tattoo ink from the skin. The example method also includes coating the treatment area with a secondary solution. The secondary solution may have an absorbent material to draw in loose ink. The example method also includes disrupting a skin barrier in the treatment area by a needle or ablative device to improve penetration of at least one of the primary solution and the secondary solution.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: December 14, 2021
    Assignee: TatXtract LLC
    Inventors: Benjamin Johnson, Tina Seitz
  • Patent number: 11191719
    Abstract: The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: December 7, 2021
    Assignee: STI Pharma, LLC
    Inventors: David F. Counts, Donald P. Cox, Anup K. Dam, Michael E. Stalhamer
  • Patent number: 11173110
    Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: November 16, 2021
    Assignee: Laboratorios Farmacéuticos Rovi, S.A.
    Inventors: Ibon Gutierro Aduriz, Guillermo Franco Rodriguez
  • Patent number: 11154471
    Abstract: Flexible solid cosmetic composition comprising sulfonate anionic surfactants, fatty esters and fatty alcohols, and cosmetic treatment method The present invention relates to an aqueous cosmetic composition in flexible solid form, comprising (i) at least 10% by weight of anionic surfactants comprising a sulfonate group, (ii) esters of fatty acid(s) comprising at least 12 carbon atoms, and (iii) fatty alcohols comprising at least 16 carbon atoms. The composition finds a particular application as a composition for cleaning or washing keratin materials, in particular the hair. The invention also relates to a cosmetic treatment method, in particular for caring for, cleaning and/or conditioning keratin materials using said composition.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: L'OREAL
    Inventors: Béatrice Thomas, Frederik Pinay
  • Patent number: 11135456
    Abstract: Hand sanitizers are provided with improved aesthetics and skin-conditioning effects, such that healthcare workers and others subject to high frequency hand hygiene requirements are encouraged to comply with said requirements. The hand sanitizers provide excellent antimicrobial efficacy and skin conditioning benefits that actually increase with increased frequency of use. The sanitizing compositions are hydroalcoholic, and contain a synergistic combination of skin-conditioning agents.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 5, 2021
    Assignee: GOJO Industries, Inc.
    Inventors: Amanda J. Copeland, Jessica Rae Tittl, Abel Saud
  • Patent number: 11090235
    Abstract: Achieving enhanced scent expression in antiperspirant compositions and methods.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: August 17, 2021
    Assignee: The Procter & Gamble Company
    Inventors: David Arthur Sturgis, Steven Michael Wujek, Sr., Phi Van Chu
  • Patent number: 11091754
    Abstract: The present disclosure addresses biologically active formulations for agricultural and other applications that comprise a solid growth substrate that defines an open cell matrix and an active population of one or more microorganisms adhered thereto. The formulation is configured to be applied directly to a plant growth environment and does not require additional isolation and/or processing steps that would separate the microorganisms from the solid growth substrate prior to deployment. The disclosure also addresses related methods.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: August 17, 2021
    Assignee: LiveGrow Bio LLC
    Inventors: Alan Stuart Wicks, Grigoriy E. Pinchuk
  • Patent number: 11089794
    Abstract: Therapeutic tea remedy mixtures in the form of beverages and ointments. Methods for making the tea remedy mixtures are described along with the benefits it provides to combat various medical ailments that frequently impair the human body.
    Type: Grant
    Filed: December 31, 2017
    Date of Patent: August 17, 2021
    Assignee: Sagrado Natural Tea Remedies, Inc.
    Inventor: Ramon Sagrado
  • Patent number: 11052028
    Abstract: The invention relates to cosmetic processes and compositions for depigmenting, lightening and/or whitening keratin materials, in particular the skin, which comprises the application of a cosmetic composition comprising thiopyridinone compounds to keratin materials.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: July 6, 2021
    Assignee: L'OREAL
    Inventor: Xavier Marat
  • Patent number: 11051510
    Abstract: The present invention relates to an agrochemical composition comprising a pesticide and an alkoxylate of the formula (I) R1-[AO]n—O—C(R3)(R4)—O—[CH2—CH2—O]m—R2??(I) where R1 is a C6-C32 aliphatic hydrocarbon group, R2 is a C1-C18 aliphatic hydrocarbon group, R3 and R4 are independently from another H or C1-C12 aliphatic hydrocarbon groups, AO is C2-C6 alkyleneoxy group, n is from 1 to 100, and m is from 0 to 10. The invention further relates to the alkoxylate. The invention further relates to a method of preparing the composition by bringing the alkoxylate and the pesticide into contact. Finally, the invention relates to a method of controlling phytopathogenic fungi and/or undesired plant growth and/or undesired insect or mite attack and/or for regulating the growth of plants.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: July 6, 2021
    Assignee: BASF SE
    Inventors: Hans-Christian Raths, Rainer Berghaus, Martin Semar
  • Patent number: 11026912
    Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: June 8, 2021
    Assignee: NEW FRONTIER LABS, LLC
    Inventors: Robert T. Streeper, Elzbieta Izbicka